Metastatic Olfactory Neuroblastoma

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Elevar Therapeutics
Elevar TherapeuticsKorea - Seoul
1 program
1
RivoceranibPhase 2Small Molecule1 trial
Active Trials
NCT06308575Withdrawn0Est. Nov 2024

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Elevar TherapeuticsRivoceranib

Clinical Trials (1)

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Start: Nov 2024Est. completion: Nov 20240
Phase 2Withdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space